You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development of liver homing PAR2 pepducins for the treatment of HepatocellularCarcinoma

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NCI

    Hepatocellular carcinoma (HCC) has become the second leading cause of cancer-related death in the world, with a 72% mortality rate in the US. The rise in incidence of HCC is due to a steady increase in the major risk factors of liver fibrosis, cirrhosis, and hepatitis B/C, with limited efficacy conferred by existing treatments at advanced stages of the disease. Systemic therapy with tyrosine kinas ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Smartphone App to Increase and Maintain Physical Activity in African American Men (FitBrothers)

    SBC: KLEIN BUENDEL, INC            Topic: 102

    Physical activity (PA) is a modifiable risk factor for a number of preventable chronic diseases, including cardiovascular disease, strokes, obesity, and diabetes. These conditions constitute health disparities for African American men. Behavioral interventions have proven to be effective in promoting increases in physical activity. While behavior change programs have been shown to assist participa ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: NIAID

    PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from pulmonary injury from viral infections, as demonstrated by the severe impact of COVID-19, which is a global pandemic that, at the time of writing, is estimated have impacted approximately 50 million people in the United States, leading to morbidity, substantial hospital and intensive care ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: 100

    PROJECT SUMMARY Optic neuritis (ON) is an acute autoimmune disease caused by immune attack on the myelin that protects the optic nerve leading to vision loss. Steroid treatments accelerate recovery of visual acuity in some patients but have no effect on other visual functions such as contrast sensitivity that are important for activities of daily life. Even with steroid treatments, 13,000 ON patie ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Development of small molecule RPN13 inhibitors for Treatment of Glioblastoma

    SBC: Up Therapeutics LLC            Topic: NCI

    Abstract. Glioblastoma (GBM) is an aggressive and deadly brain cancer with a one year median survival due to the lack of effective targeted treatments. Our goal is to develop a small molecule inhibitor targeting RPN13 protein in the 19S proteasome complex as a new drug for GBM. RPN13 is a proteasome ubiquitin receptor that recognizes ubiquitin-conjugated proteins that are thus tagged for degradati ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

    SBC: pacDNA LLC            Topic: NCI

    Project Summary/AbstractMutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeutic intervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a single mutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitors has heightened the importance of alternative methods targeting the ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons with Dementia

    SBC: HEARTHSTONE INSTITUTE LLC, THE            Topic: NIA

    PROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, andamp; Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly im ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. NewGait: A Low-Cost Rehabilitation System to Improve Post-Stroke Gait

    SBC: ELITE ATHLETE PRODUCTS INC            Topic: NICHD

    PROJECT SUMMARY More than 795,000 individuals suffer from a stroke each year in the United States, making stroke a leading cause of adult disability in the United States and worldwide. More than half of stroke survivors exhibit reduced independence and functional mobility due to stroke-related gait impairments. Despite significant advancements in post-stroke medical care and rehabilitation, curren ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. AAV-AIBP Therapy for Alzheimer's Disease

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIA

    PROJECT SUMMARY Therapy for Alzheimer’s disease and related dementias (AD/ADRD), slow-progressing neurodegenerative diseases, remains elusive. Therapeutic approaches focusing on beta amyloid (Aβ) removal from the brain or on targeting genes for which strong associations between their polymorphism and AD/ADRD are established, have had a mixed record of success. We propose a novel strategy to rev ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Developing novel technologies to monitor nociception and opioid administration during surgery and general anesthesia in order to minimize post-operative opioid requirements

    SBC: PASCALL Systems, Incorporated            Topic: NIDA

    PROJECT SUMMARY In light of the opioid crises, minimizing postoperative pain and postoperative opioid requirements to reduce chronic opioid dependency among surgical patients have become major concerns for surgeons and anesthesiologists. Effective intraoperative nociception control can mitigate these concerns. Unfortunately, existing nociceptive monitoring tools use indicators that are inherently ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government